The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).
John Martignetti
Research Funding - Karyopharm Therapeutics
Albiruni R.A. Razak
Research Funding - Karyopharm Therapeutics
Ying Chen
Research Funding - Karyopharm Therapeutics
Nashat Y. Gabrail
No relevant relationships to disclose
John F. Gerecitano
No relevant relationships to disclose
Catalina Camacho
Research Funding - Karyopharm Therapeutics
Elena Pereira
Research Funding - Karyopharm Therapeutics
Peter Remsen Dottino
Research Funding - Karyopharm Therapeutics
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Dilara McCauley
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Tami Rashal
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Jean-Richard Saint-Martin
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Eran Shacham
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Darcy Vincett
No relevant relationships to disclose
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Mansoor Raza Mirza
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Morten Sorensen
Research Funding - Karyopharm Therapeutics